1. Signaling Pathways
  2. Immunology/Inflammation
  3. Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most (clusters of differentiation)CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells[1][2].

Transmembrane Glycoprotein Related Products (144):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990496
    Anti-PVRIG Antibody (COM701)
    Inhibitor
    Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-PVRIG Antibody (COM701)
  • HY-128128
    ASN04421891
    Modulator 99.00%
    ASN04421891 is a potent GPR17 receptor modulator, with an EC50 of 3.67 nM in [35S]GTPγS binding assay. ASN04421891 can be used for neurodegenerative diseases research.
    ASN04421891
  • HY-N8102
    Echinocystic acid 28-O-β-D-glucoside
    Inhibitor 99.11%
    Echinocystic acid 28-O-β-D-glucoside is a metabolite of Echinocystic acid by microbial oxidation and glucosidation. Echinocystic acid 28-O-β-D-glucoside is a tissue factor pathway inhibitor, with an IC50 of 10.61 nM.
    Echinocystic acid 28-O-β-D-glucoside
  • HY-P1615
    Cenupatide
    Inhibitor 99.62%
    Cenupatide (UPARANT) is a Urokinase-type plasminogen activator receptor (uPAR) inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy.
    Cenupatide
  • HY-P99120
    Anti-Mouse CD11a Antibody (FD441.8)
    Inhibitor
    Anti-Mouse CD11a Antibody is an anti-mouse CD11a IgG2b antibody inhibitor derived from the host Rat.
    Anti-Mouse CD11a Antibody (FD441.8)
  • HY-P99381
    XmAb 5592
    Inhibitor 99.51%
    XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).
    XmAb 5592
  • HY-P990328
    Anti-AGER/RAGE Antibody (XT-M4)
    Inhibitor ≥99.0%
    Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-AGER/RAGE Antibody (XT-M4)
  • HY-P990264
    Anti-Mouse CD70 Antibody (FR70)
    Inhibitor
    Anti-Mouse CD70 Antibody (FR70) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse CD70.
    Anti-Mouse CD70 Antibody (FR70)
  • HY-P990317
    AGS-67E
    Inhibitor
    AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
    AGS-67E
  • HY-P990092
    Rolistobart
    Inhibitor
    Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic.
    Rolistobart
  • HY-P1822
    BDC2.5 mimotope 1040-31
    Agonist 98.00%
    BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg+ T cells.
    BDC2.5 mimotope 1040-31
  • HY-157281
    Photolumazine III
    99.96%
    Photolumazine III is a MHC class I related-1 molecule (MR1) antigen.
    Photolumazine III
  • HY-14921
    Elsibucol
    Inhibitor 99.35%
    Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury.
    Elsibucol
  • HY-P990360
    Anti-CD9 Antibody
    99.52%
    The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG2 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD9 Antibody
  • HY-P10495
    GPR110 peptide agonist P12
    Activator
    GPR110 peptide agonist P12 is a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 can be used in the study of developmental disorders and cancers related to GPR110.
    GPR110 peptide agonist P12
  • HY-P99674
    Ivicentamab
    Inhibitor
    Ivicentamab (GEN-3009) is an IgG1κ-type bispecific antibody targeting different epitopes of CD37. Ivicentamab can be used for cancer research.
    Ivicentamab
  • HY-P990277
    Anti-Mouse CD31/PECAM-1 Antibody (390)
    Inhibitor
    Anti-Mouse CD31/PECAM-1 Antibody (390) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD31/PECAM-1.
    Anti-Mouse CD31/PECAM-1 Antibody (390)
  • HY-P990642
    Oportuzumab
    Inhibitor 99.62%
    Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Oportuzumab
  • HY-P990031
    Dargistotug
    99.36%
    Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.
    Dargistotug
  • HY-P990975
    Birinkibart
    HY-P990975 is an CSF2RB-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Birinkibart